Cosyn Precision Medicin

Comorbidity and Synapse Biology in Clinically Overlapping Psychiatric Disorders.

COSYN is a unique pan-European project bringing together leading experts from the relevant clinical fields, genomics, stem cell biology, neurobiology, and strong participation of LE Pharma.

COSYN aims to address the basis of intellectual disabilities (ID), autism, and schizophrenia by studying the genes and pathways involved in this process and by identifying the interactions through which disease develops in normal and in disease conditions, with an emphasis on synaptic function, as early steps of neuropsychiatric disorders are expected to impact synapse function.

COSYN will identify better, more appropriate targets for therapy, provide clinicians and LE Pharma a better understanding of the molecular basis of the diseases at hand, and develop a new disease classification and new cellular assays and drug targets.